Momotaro-Gene
Okayama, Japan· Est.
A Japanese biotech developing REIC/Dkk-3 gene therapy for solid tumors, with a lead program in malignant glioma.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A Japanese biotech developing REIC/Dkk-3 gene therapy for solid tumors, with a lead program in malignant glioma.
Oncology
Technology Platform
Adenovirus vector-based gene delivery platform centered on the tumor-suppressing REIC/Dkk-3 gene, which induces selective apoptosis in cancer cells and modulates the tumor microenvironment.
Opportunities
Opportunities include expanding Ad-SGE-REIC into other solid tumor indications like liver cancer and developing synergistic combination regimens with checkpoint inhibitors to enhance anti-tumor immunity.
Risk Factors
Key risks include clinical failure of its lead asset, high competition in oncology gene therapy, reliance on a single technology platform, and challenges in scaling as a small, pre-revenue company.
Competitive Landscape
Competes with other viral gene therapy developers for solid tumors (e.g., DNAtrix, TILT Biotherapeutics). Differentiation is its unique REIC/Dkk-3 mechanism aiming for tumor-selective apoptosis and immune activation, but it is earlier-stage than some peers.